Viewing Study NCT07171827


Ignite Creation Date: 2026-03-26 @ 3:21 PM
Ignite Modification Date: 2026-04-05 @ 3:02 PM
Study NCT ID: NCT07171827
Status: COMPLETED
Last Update Posted: 2025-09-15
First Post: 2025-09-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Sponsor: Helwan University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module